Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

5/30/24 7:25:43 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADAP

Date	Price Target	Rating	Analyst
7/30/2024	$4.00	Buy	H.C. Wainwright
5/30/2024	$3.15	Sector Outperform	Scotiabank
3/24/2023	$3.60	Buy	Bryan Garnier
1/3/2023	$5.00	Neutral → Buy	Guggenheim
11/9/2022	$9.00	Neutral → Buy	Mizuho
9/22/2021	$6.00 → $7.00	Equal-Weight	Wells Fargo
9/13/2021	$6.00 → $7.00	Market Perform	SVB Leerink
9/7/2021	$5.00 → $6.00	Market Perform	SVB Leerink